MedTrace Logo

Cabergoline in Metastatic Breast Cancer

NCT01730729 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-09-17

Study results available
· View outcomes & findings →

Summary

Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood.

The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor.

Conditions

  • Recurrent Breast Cancer
  • Stage IV Breast Cancer

Interventions

DRUG

cabergoline

Given orally

Sponsors & Collaborators

Principal Investigators

  • Virginia Kaklamani · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-11
Primary Completion
2015-12-15
Completion
2017-10-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01730729 on ClinicalTrials.gov